Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: A Children's Oncology Group study (CCG‐1941)

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Pediatric Blood & Cancer

• Publication date

  2006-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/pbc.20713PMID 16425271
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia.

  2005cited by this paper
• Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia.

  2005cited by this paper
• Cellular drug resistance in childhood leukemia

  2005cited by this paper
• Asparaginase Antibody and Asparaginase Activity in Children With Higher-Risk Acute Lymphoblastic Leukemia: Children's Cancer Group Study CCG-1961

  2004cited by this paper
• L-asparaginase kills lymphoma cells by apoptosis

  2004cited by this paper
• Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL

  2003cited by this paper
• A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study.

  2002influential reference
• Development of a double-drug-resistant human leukemia model to cytosine arabinoside and L-asparaginase: evaluation of cross-resistance to other treatment modalities.

  2001cited by this paper
• Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells.

  2001cited by this paper
• Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells.

  2001cited by this paper
• Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a pediatric oncology group study

  2000cited by this paper
• Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study.

  2000cited by this paper
• Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia.

  1999cited by this paper
• The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia.

  1999cited by this paper
• Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study

  1999cited by this paper
• The Three Asparaginases

  1999cited by this paper
• Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia

  1998cited by this paper
• Cell cycle arrest and apoptosis of leukemia cells induced by L-asparaginase

  1997cited by this paper
• Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells.

  1997cited by this paper
• In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia.

  1997cited by this paper
• Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia

  1997cited by this paper
• Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations.

  1996cited by this paper
• L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase.

  1996cited by this paper
• Characterization of apoptotic phenomena induced by treatment with L-asparaginase in NIH3T3 cells.

  1995cited by this paper
• Determination of L-asparagine in biological samples in the presence of L-asparaginase.

  1994cited by this paper
• Comparative pharmacokinetic studies of three asparaginase preparations.

  1993cited by this paper
• Measurement of serum L-asparagine in the presence of L-asparaginase requires the presence of an L-asparaginase inhibitor.

  1991cited by this paper
• Molecular and genetic characterization of human cell lines resistant tol-asparaginase and albizziin

  1990cited by this paper
• Biochemical characterization of U937 cells resistant to L-asparaginase: the role of asparagine synthetase.

  1989cited by this paper
• Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement.

  1986cited by this paper
• Sensitive analysis of asparagine and glutamine in physiological fluids and cells by precolumn derivatization with phenylisothiocyanate and reversed-phase high-performance liquid chromatography.

  1986cited by this paper
• Anaphylaxis to L-asparaginase during treatment for acute lymphoblastic leukemia in children--evidence of a complement-mediated mechanism.

  1985cited by this paper
• Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia.

  1983cited by this paper
• L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans.

  1981cited by this paper
• Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia.

  1979cited by this paper
• Immunological aspects of L-asparaginase treatment in children with lymphoproliferative disease.

  1976cited by this paper
• [Characteristics of asparaginase from Escherichia coli at different stages of purification].

  1976cited by this paper
• Nutritional effects on precursor uptake and compartmentalization of intracellular pools in relation to RNA synthesis.

  1975cited by this paper
• Studies on antibody formation in patients treated with L-asparaginase.

  1970cited by this paper
• Asparaginase and cancer--yesterday and today.

  1970cited by this paper
• Neutralizing precipitin in the serum of a patient treated with L-asparaginase.

  1969cited by this paper

• l‐Asparaginase Bio‐Betters: Insight Into Current Formulations, Optimization Strategies and Future Bioengineering Frontiers in Anti‐Cancer Drug Development

  2024cites this paper
• The potential of methioninase for cancer treatment.

  2024cites this paper
• l-asparaginase anti-tumor activity in pancreatic cancer is dependent on its glutaminase activity and resistance is mediated by glutamine synthetase.

  2023cites this paper
• Asparaginase activity monitoring in pediatric acute lymphoblastic leukemia: A cross‐sectional nationwide study in Spain

  2022cites this paper
• Depletion of d‐ and l‐asparagine in cerebrospinal fluid in acute lymphoblastic leukemia during PEGasparaginase therapy

  2022cites this paper
• Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study

  2022cites this paper
• L-аспарагиназa

  2022cites this paper
• Predictive markers for efficiency of the amino-acid deprivation therapies in cancer

  2022cites this paper
• BLCTT_A_245210 25..40

  2021cites this paper
• Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase

  2021cites this paper
• Clinical Utility of Pegaspargase in Children, Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia: A Review

  2021cites this paper
• 左旋门冬酰胺酶对伯基特淋巴瘤细胞株增殖、细胞周期及凋亡的影响

  2021cites this paper
• Nano-pharmacokinetics: biodistribution and toxicology

  2021cites this paper
• How much asparaginase is needed for optimal outcome in childhood acute lymphoblastic leukaemia? A systematic review.

  2021cites this paper
• Asparaginase-Associated Pancreatitis in Pediatric Patients with Acute Lymphoblastic Leukemia: Current Perspectives

  2021cites this paper
• Asparagine: A Metabolite to Be Targeted in Cancers

  2021cites this paper
• Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion

  2020cites this paper
• FPGS relapse-specific mutations in relapsed childhood acute lymphoblastic leukemia

  2020cites this paper
• Functional and structural evaluation of the antileukaemic enzyme l-asparaginase II expressed at low temperature by different Escherichia coli strains

  2020cites this paper
• Consensus protocols for animal experimentation and nanomedicine trials at clinical stage in breast cancer

  2020cites this paper
• PEGylated E. coli asparaginase desensitization: an effective and feasible option for pediatric patients with acute lymphoblastic leukemia who have developed hypersensitivity to pegaspargase in the absence of asparaginase Erwinia chrysanthemi availability

  2019cites this paper
• Universal premedication and therapeutic drug monitoring for asparaginase‐based therapy prevents infusion‐associated acute adverse events and drug substitutions

  2019cites this paper
• Assessment of l-Asparaginase Pharmacodynamics in Mouse Models of Cancer

  2019cites this paper
• Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia

  2018cites this paper
• Monitoring of asparagine depletion and anti-l-asparaginase antibodies in adult acute lymphoblastic leukemia treated in the pediatric-inspired GRAALL-2005 trial

  2018cites this paper
• Asparaginase pharmacology: challenges still to be faced

  2017cites this paper
• Plasma asparaginase activity, asparagine concentration, and toxicity after administration of Erwinia asparaginase in children and young adults with acute lymphoblastic leukemia: Phase I/II clinical trial in Japan

  2017cites this paper
• Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia

  2017cites this paper
• Nanomedicine applied to translational oncology: A future perspective on cancer treatment.

  2016cites this paper
• Erythrocyte encapsulated l-asparaginase (GRASPA) in acute leukemia.

  2016cites this paper
• Asparaginase pharmacokinetics and implications of therapeutic drug monitoring

  2015cites this paper
• A Phase 2 study of L‐asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL‐SA2‐2008 study

  2015cites this paper
• Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia.

  2015cites this paper
• Immediate Cooling Does Not Prevent the Ex Vivo Hydrolysis of L-Asparagine by Asparaginase

  2014cites this paper
• Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia

  2014cites this paper
• Asparaginase in the treatment of non-ALL hematologic malignancies

  2014cites this paper
• Asparaginase-II : Escherichia coli of Epitopes Improve Antileukemic Activities Mutations in Subunit Interface and B-cell Enzymology :

  2014cites this paper
• Nanomedicine in action: an overview of cancer nanomedicine on the market and in clinical trials

  2013cites this paper
• Leukemia Group B Study 9511 improved outcomes in adult acute lymphoblastic leukemia: Cancer and Effective asparagine depletion with pegylated asparaginase results in

  2013cites this paper
• Mutations in Subunit Interface and B-cell Epitopes Improve Antileukemic Activities of Escherichia coli Asparaginase-II

  2013cites this paper
• Adipocytes cause leukemia cell resistance to L-asparaginase via release of glutamine.

  2013cites this paper
• Asparagine and aspartic acid concentrations in bone marrow versus peripheral blood during Berlin–Frankfurt–Münster-based induction therapy for childhood acute lymphoblastic leukemia

  2012cites this paper
• Curcumin potentiates antitumor activity of l-asparaginase via inhibition of the AKT signaling pathway in acute lymphoblastic leukemia

  2012cites this paper
• Bacterial Asparaginase: A Potential Antineoplastic Agent for Treatment of Acute Lymphoblastic Leukemia

  2012cites this paper
• Asparaginases: biochemical pharmacology and modes of drug resistance.

  2012cites this paper
• Asparaginases: A Successful Class of Drugs Against Leukemias and Lymphomas

  2011cites this paper
• Rational engineering of L-asparaginase reveals importance of dual activity for cancer cell toxicity.

  2011cites this paper
• activity for cancer cell toxicity Rational engineering of L-asparaginase reveals importance of dual

  2011cites this paper
• Structure-function relationships and clinical applications of L-asparaginases.

  2010cites this paper
• Silent hypersensitivity to Escherichia coli asparaginase in children with acute lymphoblastic leukemia

  2010cites this paper
• Comparison of Native E. coli and PEG Asparaginase Pharmacokinetics and Pharmacodynamics in Pediatric Acute Lymphoblastic Leukemia

  2009cites this paper
• Use of L-asparaginase in acute lymphoblastic leukemia: recommendations of the Polish Adult Leukemia Group.

  2008cites this paper
• Title: Models of Asparaginase and Asparagine Pharmacokinetics and Pharmacodynamics in Pediatric Acute Lymphoblastic Leukemia

  2008cites this paper
• Clinical Pharmacology of Asparaginases in the United States: Asparaginase Population Pharmacokinetic and Pharmacodynamic (PK-PD) Models (NONMEM) in Adult and Pediatric ALL Patients

  2007cites this paper
• Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.

  2007cites this paper
• Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia

  2006influential citation
• Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511.

  2005cites this paper